Limit on Royalty Reductions. Notwithstanding anything to the contrary in [***], in no event shall the royalties owed under Section 8.3.1 with respect to a Licensed Product in a country be reduced by operation of Section 8.3.2(a) and (b) by more than [***] percent ([***]%) of what would otherwise be owed under Section 8.3.1 with respect to such Licensed Product in such country. For purposes of clarity, this limitation [***].
Limit on Royalty Reductions. In no event shall the royalties owed under Section 4.5.1(a) (Royalty Rate), with respect to a Collaboration Product in a country be reduced by operation of Section 4.5.1(c) (Royalty Stacking), by more than “[***]”percent (“[***]”%) of what would otherwise be owed to Intec Pharma under Section 4.5.1(a) (Royalty Rate); provided, however, that if any amount payable to a Third Party and otherwise permitted to be offset against the royalties due to Intec Pharma with respect to a Collaboration Product pursuant to Section 4.5.1(c) (Royalty Stacking) cannot be offset against such royalties due to the provisions of this Section 4.5.1(d), such unused amount may be carried forward and offset against royalties due with respect to such Collaboration Product in future royalty periods.
Limit on Royalty Reductions. Notwithstanding anything to the contrary in this Article in no event shall the royalties owed under Article 7.2 with respect to a Covered Product in a country be reduced by operation of any subsection of this Article 7.4 by more than an aggregate of [***] of what would otherwise be owed under Article 7.2 with respect to [***]. [***] = [CONFIDENTIAL PORTION HAS BEEN OMITTED BECAUSE IT (I) IS NOT MATERIAL AND (II) WOULD BE COMPETITIVELY HARMFUL IF PUBLICLY DISCLOSED]
Limit on Royalty Reductions. Notwithstanding anything to the contrary, in no circumstances will the royalties payable to Alnylam under this Section 5.3 in any [* * *] be reduced, as a result of Sections 5.3.3 and 5.3.4 in the aggregate below [* * *] of the royalties otherwise payable under this Section 5.3. In addition, none of the royalty reductions in Sections 5.3.3 and 5.3.4 shall apply in any [* * *] in which the royalties payable to Alnylam are reduced pursuant to Section 5.3.5.
Limit on Royalty Reductions. In no event shall the Royalties owed under Section 8.6.1, with respect to a Product in a country, be reduced by operation of Sections 8.6.3(a) or 8.6.3(b) by more than an aggregate of [* * *] of what would otherwise be owed under the table set forth in Section 8.6.1 with respect to such Product in such country. To the extent that the reductions under Sections 8.6.3(a) or 8.6.3(b) would, but for the limitation in the foregoing sentence, result in a Royalty that would be less than [* * *] of what would otherwise be owed, the difference between such lower Royalty and the Royalty payable due to the forgoing limitation shall be carried forward and deducted against any and all subsequent payments due to Dicerna from Novo hereunder until the end of the Royalty Term. For the avoidance of doubt, the foregoing limitation on reductions does not affect Section 8.6.3(c), and any reduction under Section 8.6.3(c) shall be made net of any reductions made pursuant to Sections 8.6.3(a) and 8.6.3(b) (e.g., if the maximum reduction of [* * *] is reached under Sections 8.6.3(a) and 8.6.3(b) and the reduction of [* * *] in Section 8.6.3(c) is also reached, the net Royalty will be [* * *] of what would otherwise be owed).
Limit on Royalty Reductions. In no event shall the Royalties owed under Sections 8.4.1 or Section 8.4.2, as applicable, with respect to a Product in a country be reduced by operation of Sections 8.4.4(a), 8.4.4(b) or 8.4.4(c) by ***Text Omitted and Filed Separately with the Securities and Exchange Commission. Confidential Treatment Requested Under
Limit on Royalty Reductions. Notwithstanding Sections 4.6.1(a)(ii), 4.6.1(b)(ii) or 4.6.1(c), in no event shall the royalties owed under Section 4.6.1(a)(i) or Section 4.6.1(b)(i), with respect to a Royalty-Bearing Product in a country be reduced by operation of Section 4.6.1(c), together with either Section 4.6.1(a)(ii) or Section 4.6.1(b)(ii), [***] percent ([***]%) of what would otherwise be owed under 4.6.1(a)(i) or Section 4.6.1(b)(i) with respect to such Royalty-Bearing Product in such country. Portions of this Exhibit were omitted and have been filed separately with the Secretary of the Commission pursuant to the Company’s application requesting confidential treatment under Rule 24b-2 of the Securities Exchange Act of 1934, as amended.
Limit on Royalty Reductions. Notwithstanding the royalty reductions set forth above under Sections 8.4.3, 8.4.4 and 8.4.5, under no circumstances shall the royalty rate used to calculate the royalty payment payable under Section 8.4.1 be less than [*]% of the royalty rate set forth above in Table 2 in Section 8.4.1.
Limit on Royalty Reductions. Notwithstanding anything to the contrary, except as provided in Section 5.3.5, in no circumstances will the royalties payable to Centrexion under this Section 5.3 in any Calendar Quarter be reduced, as a result of Sections 5.3.3 and 5.3.4 in the aggregate below [***] percent ([***]%) of the royalties otherwise payable under this Section 5.3. Certain information in this Exhibit marked as [***] has been excluded pursuant to Regulation S-K, Item 601(b)(10). Such excluded information is not material and would be competitively harmful if publicly disclosed.
Limit on Royalty Reductions. Notwithstanding Section 4.4.1(a)(ii), in no event shall the royalties owed under Section 4.4.1(a)(i), with respect to a Product in a country be reduced by operation of Section 4.4.1(b), together with Section 4.4.1(a)(ii), [***] percent ([***]%) of what would otherwise be owed under 4.4.1(a)(i) with respect to such Product in such country.
